RxDoctor Payments Data

Eric Walter, DPM

Foot Surgery · Bronx, NYNPI 1063410470

Payments from drug & device makers

$1,691in general payments, 2019–2025

Across 35 payments — averaging $48.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$611
  • Treace Medical Concepts, Inc.$292
  • Johnson & Johnson$121
  • Osiris Therapeutics Inc.$120
  • Advanced Oxygen Therapy Inc.$86
  • Zimmer Biomet$86
  • plus $374 from 8 others

What the payments were for

  • Food & beverage$1,691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,691 in reported general payments places this provider in the 70th percentile of 294 foot surgery providers in New York.

See all foot surgery providers in New York

Medicare billing

Part B allowed, 2024
$76,976
Medicare patients
335
Services billed
1,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CiclopiroxCiclopirox Olamine765$24,441
SantylCollagenase Clostridium Hist.22$7,777
Diclofenac Sodium226$5,413
Ammonium Lactate220$4,912
Pregabalin15$1,288
Gabapentin119$813
Triamcinolone Acetonide114$584
Clotrimazole15$473
Colchicine17$451
Celecoxib13$329
Terbinafine Hcl60$328
Meloxicam146$315
Mupirocin44$279
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$155
Silver Sulfadiazine16$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$50$7,77722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 294 foot surgery providers in New York.

Other foot surgery in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →